Form 8-K - Current report:
SEC Accession No. 0001213900-25-010711
Filing Date
2025-02-06
Accepted
2025-02-06 06:38:57
Documents
16
Period of Report
2025-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0230164-8k_relmada.htm   iXBRL 8-K 45537
2 ASSET PURCHASE AGREEMENT, BY AND BETWEEN RELMADA THERAPEUTICS, INC. AND ASARINA ea023016401ex10-1_relmada.htm EX-10.1 99671
3 PRESS RELEASE ISSUED BY RELMADA THERAPEUTICS, INC. DATED FEBRUARY 6, 2025 ea023016401ex99-1_relmada.htm EX-99.1 20090
4 GRAPHIC ex99-1_001.jpg GRAPHIC 5237
  Complete submission text file 0001213900-25-010711.txt   378029

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE rlmd-20250203.xsd EX-101.SCH 3012
6 XBRL LABEL FILE rlmd-20250203_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE rlmd-20250203_pre.xml EX-101.PRE 22357
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0230164-8k_relmada_htm.xml XML 3694
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 25595366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)